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Abstract
Background: Anergy is a key mechanism controlling expression of autoreactive B cells and a major site for failed regula-
tion in autoimmune diseases. Yet the molecular basis for this differentiated cell state remains poorly understood. The current 
lack of well-characterized surface or molecular markers hinders the isolation of anergic cells for further study. Global gene 
proﬁ  ling recently identiﬁ  ed transcripts whose expression differentiates anergic from naïve B cells in model mouse systems. 
The objective of the current study was to evaluate the molecular and cellular processes that differentiate anergic cells that 
develop in the healthy C57BL/6 (B6) milieu from those that develop in the autoimmune-prone MRL/MpJ (MRL) background. 
This approach takes advantage of B6 and MRL mice bearing an anti-laminin Ig transgene with a well characterized anergic 
B cell phenotype.
Results: Global gene expression was evaluated in puriﬁ  ed transgenic B cells using Operon version 3.0 oligonucleotide 
microarray assaying 31,000 oligoprobes. Genes with a 2-fold expression difference in B6 as compared to MRL anergic 
B cells were identiﬁ  ed. Expression of selected genes was conﬁ  rmed using quantitative RT-PCR. This approach identiﬁ  ed 
43 probes corresponding to 37 characterized genes, including Ptpn22, CD74, Birc1f/Naip, and Ctla4, as differentially 
expressed in anergic B cells in the two strains. Gene Ontology classiﬁ  cation identiﬁ  ed differentiation, cell cycle, proliferation, 
development, apoptosis, and cell death as prominently represented ontology groups. Ingenuity Pathway Analysis identiﬁ  ed 
two major networks incorporating 27 qualifying genes. Network 1 centers on beta-estradiol and TP53, and Network 
2 encompasses RB1, p38 MAPK, and NFkB cell growth, proliferation, and cell cycle signaling pathways.
Conclusion: Using microarray analysis we identiﬁ  ed 37 characterized genes and two functional pathways engaged in 
maintenance of B cell anergy for which expression is distorted by underlying autoimmune genetic susceptibility. This 
approach identifes a new biological role for multiple genes and potential new therapeutic targets in autoimmunity.
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Introduction
Autoimmune diseases affect an estimated 6% of the population, causing signiﬁ  cant morbidity and pos-
ing a major burden on the health care system (Nossal, 2001; Siatskas et al. 2006). Most current therapies 
such as steroids, cytotoxic agents, and broadly speciﬁ  c monoclonal antibodies rely on broad immuno-
suppression that is variably effective and carries the risk of infection, cancer, osteoporosis, sterility and 
other side effects. Novel interventions that act in a disease- or antigen-speciﬁ  c manner are urgently 
needed (Wolfraim, 2006), but their development requires a better understanding of the molecular basis 
for loss of immune tolerance that underlies disease pathogenesis.
Antigen-speciﬁ  c tolerance mechanisms that normally regulate autoreactive lymphocytes include cell 
deletion, receptor editing and anergy. Of these, B cell anergy is a particularly attractive target for thera-
peutic immune intervention in vivo, as suggested in preclinical models of lupus in which restoration of 
B cell expression of inhibitory FcγRIIB ameliorates nephritis (McGaha et al. 2005). Anergy is a ﬁ  nal 
safeguard against autoreactivity when editing or deletion fails, and in autoimmune individuals is itself a 
major site of failed tolerance (Cambier et al. 2007; Conrad et al. 2007). The murine lupus-associated 
Ly108 susceptibility allele at the Sle1z/Sle1bz locus, for which there is an orthologous human locus, 
impairs B cell anergy as well as editing and deletion (Kumar et al. 2006). Anergy is a major control point 336
Clark et al
Biomarker Insights 2008:3 
in fulminant lupus nephritis in mouse models. B 
cell-speciﬁ  c inactivation of Cbl/Cbl-b leads to 
impaired anergy induction and severe immune 
complex glomerulonephritis (Kitaura et al. 2007). 
Yet little is known about the molecular blueprint of 
this important regulatory mechanism.
A major hurdle to therapeutically manipulating 
anergy in patients is the lack of information regard-
ing anergy-speciﬁ  c markers or pathways to guide 
isolation of anergic B cells in man (Cambier et al. 
2007). Unlike natural regulatory T cells, for which 
identiﬁ  cation is aided by expression of the surface 
marker CD25+ and the intracellular foxp3 master 
regulator, B cell anergy is currently deﬁ  ned almost 
exclusively at the functional level. Although aner-
gic cells are thought to comprise a signiﬁ  cant 
proportion of splenic B cells, this tissue is not 
available for routine sampling in man. In contrast, 
anergic cells are estimated to comprise only 
1%–5% of human peripheral B cells (Duty et al. 
2006), which in turn comprise only approximately 
5% of peripheral blood mononuclear cells. Alterna-
tive sources of anergic cells, such as in vitro toler-
ization, are limited due to the brief survival of 
unstimulated human B cells in culture.
This relative inaccessibility of human anergic 
cells led us to initiate studies using our LamH Ig 
transgenic mouse model system. Transgenic LamH 
Ig bind to the laminin alpha1-chain expressed in 
basement membranes in the kidney and other 
organs and targeted by autoantibodies in human 
lupus (Abrahamson et al. 2003; Amital et al. 2005; 
Amital et al. 2007). LamH Ig transgenic mice have 
a well-deﬁ  ned tolerance phenotype that includes 
anergy in peripheral B cells that escape central 
deletion (Brady et al. 2004; Foster et al. 2006; 
Hecox and Foster, 2004; Rudolph et al. 2002). 
Anergy is a state of cell differentiation that results 
from B cell receptor signaling in the absence of 
costimulation such that the cell fails to activate on 
subsequent engagement of antigen. Anergy in the 
LamH Tg model is characterized by impaired 
in vitro transgenic B cell proliferation and differ-
entiation in response to Ig crosslinking and mito-
gen, compared to non-transgenic littermate B cells 
(Brady et al. 2004; Foster et al. 2006; Rudolph 
et al. 2002). This is accompanied by absence of 
serum transgenic autoantibodies, failure to recover 
autoreactive Tg monoclonal antibodies by fusion, 
shortened B cell life span, and, altered surface 
expression of activation and maturational markers. 
These Ig transgenic mice thus provide a reliable 
source of anergic B cells amenable to transcriptional 
interrogation.
Query of anergic cells by microarray permits 
measurement of relative levels of mRNA for thou-
sands of unique genes and thus monitors a large 
number of putative regulatory pathways. This 
approach also allows screening for global changes 
in the absence of preconceived notions regarding 
gene function, in contrast to studies that focus on 
candidate molecules, pathways or genes on the 
basis of known roles in immune signaling or 
inﬂ  ammation. Pioneering work by Glynne et al. 
used the hen egg lysozyme (HEL) Ig Tg model 
system and an early generation Affymetrix micro-
array spotted with ∼4,000 murine genes. These 
investigators identifed a small subset of inhibitory 
genes differentially upregulated in anti-HEL aner-
gic B cells, as compared to non-tolerant B cells, 
probed six hours after receptor stimulation (Glynne 
et al. 2000a; Glynne et al. 2000b).
To further explore the molecular basis of anergy 
involving a disease-relevant antigen, we used rep-
resentational difference analysis (RDA) and the 
Operon v.3.0 oligoarray representing 31,000 
elements to identify transcripts differentially regu-
lated in anergic Tg as compared to naïve non-
transgenic B cells (Clark et al. 2007). Results were 
initially mined for genes whose expression varied 
by 2-fold when comparing anergic to naïve 
cells in both the normal C57Bl/6 (B6) and the 
autoimmune-susceptible MRL/MpJ (MRL) strains, 
and selected results were validated by qPCR and 
Western blot. We identiﬁ  ed approximately 60 genes 
deemed likely to include core regulatory molecules 
engaged in maintenance of anergy. This included 
genes encoding multifunctional proteins not previ-
ously implicated in B cell biology or tolerance but 
with roles in processes fundamental to the tolerance 
phenotype. Moreover, because their differential 
expression was common to B6 and autoimmune 
MRL anergic cells, these genes partially deﬁ  ne 
minimal molecular requirements for anergy and 
allow us to establish a genetic proﬁ  le of an anergic 
B cell.
Although both the normal B6 and the autoim-
mune MRL strains exhibited intact B cell tolerance 
in our anti-laminin Ig Tg, we hypothesized that 
subtle differences in the anergic phenotype of 
B cells between the strains may nonetheless 
contribute to the ultimate loss of tolerance leading 
to development of lupus in autoimmune MRL 
mice. In the current analysis of our gene expression 337
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database, we identiﬁ  ed a distinct subset of genes 
that signiﬁ  cantly differ in expression in autoim-
mune MRL as compared to B6 anergic cells. The 
majority of identiﬁ  ed genes group into one of two 
functional networks known to regulate cell growth, 
signaling and apoptosis. Collectively, these studies 
provide novel insight into the biology of anergy 
and autoimmune genetic susceptibility. Moreover, 
identiﬁ  cation of genes over or under expressed in 
anergic MRL B cells prone to tolerance failure 
suggests potential new biomarkers of autoim-
mune risk. Hopefully these ﬁ  ndings will help guide 
efforts to identify the elusive anergic cell in man 
and to develop novel interventions to enhance 
tolerance in patients.
Materials and Methods
Animals
All studies and procedures were approved by the 
Duke University and the Durham Veterans Affairs 
Medical Center Animal Care and Use Committees. 
Cloning of the anti-laminin LamH CμH chain 
construct and thorough characterization of trans-
genic (Tg+) mice on both the standard B6 and the 
autoimmune MRL backgrounds have been 
described (Brady et al. 2004; Foster and Fitzsimons, 
1998; Rudolph et al. 2002). Hemizygous Tg+ and 
non-transgenic (non-Tg) mice of either sex were 
reared under conventional conditions. B6 and MRL 
breeders were obtained from The Jackson Labora-
tory (Bar Harbor, ME, U.S.A.).
B cell isolation
B cell isolation, RNA preparation, and microarray 
processing were performed as previously described 
(Clark et al. 2007). Brieﬂ  y, splenocytes were iso-
lated from LamH Tg+ and non-Tg control mice, 
matched for age and gender when possible. Sple-
nocytes from each background were pooled by 
transgene status, and red cells removed by hypo-
tonic lysis. Remaining cells were magnetically 
separated using a B cell negative selection kit 
(Miltenyi Biotech, Auburn, CA, U.S.A.) per the 
manufacturer’s protocol. The resulting B cell 
enriched population was then incubated with anti-
B220/CD45R-PE ﬂ  uorescently labeled antibody 
(Pharmingen, San Diego, CA, U.S.A.) and positive 
cells sorted and collected using a FACS DiVa ﬂ  ow 
cytometer (Becton Dickinson, Franklin Lakes, NJ, 
U.S.A.). Resulting B cell populations were gener-
ally 95% B220+. Cells were then either collected 
directly (t = 0) into buffer RLT from the Rneasy 
kit (Qiagen, Valencia, CA, U.S.A.) or were plated 
in proliferation media: RPMI 1640 supplemented 
with 10% heat-inactivated fetal bovine serum, 
2 mM L-glutamine, 25 mM HEPES, 0.1 mM non-
essential amino acids, 1 mM sodium pyruvate, 
100 U/mL penicillin-streptomycin, 0.3% NaHCO3, 
and 2-mercaptoethanol (all supplements from Life 
Technologies, Carlsbad, CA, U.S.A.). Cultured 
cells were stimulated with 20 μg/mL anti-IgM 
F(ab’)2 (Pierce, Rockford, IL, U.S.A.) for 24 hours 
to crosslink B cell receptors simulating antigen 
contact. Following culture, viable cells were iso-
lated using Lympholyte M (Cedarlane, Hornby, 
Ontario, Canada) and resuspended in buffer RLT 
(Qiagen). Lysed cells were homogenized using 
Qiashredder and stored at –80C until processing.
For qPCR studies: Splenocytes were harvested 
as described above. B cells were isolated by mag-
netic negative selection without subsequent FACS 
sorting. To enhance B cell purity in the Tg+ mice, 
1/800th volume of additional anti-CD11b-biotin 
was spiked into the manufacturer’s antibody cock-
tail to more completely remove contaminating 
cells. Puriﬁ  ed cells were collected directly (t = 0) 
into buffer RLT from the RNeasy kit (Qiagen).
RNA isolation and ampliﬁ  cation
RNA was extracted from puriﬁ  ed B cells using the 
Rneasy mini- or midi-kit, depending on cell count, 
per the manufacturer’s instructions (Qiagen). On-
column DNase digestion was simultaneously 
performed. For microarray studies, RNA was 
reverse transcribed and ampliﬁ  ed for two rounds 
using the MessageAmp in vitro transcription 
kit (Ambion, Austin, TX, U.S.A.). For qPCR 
veriﬁ  cation, RNA was reverse transcribed using 
random primers and the ImPromII kit (Promega, 
Madison, WI, U.S.A.) per the manufacturer’s 
instructions.
Microarray
Anergic B cells were cohybridized against naïve 
B cells to microarray chips spotted with the 
Operon mouse v.3.0 oligo probe set, as previously 
described (Clark et al. 2007). For each biological 
replicate, dye reversed duplicate hybridizations 
were performed to eliminate dye bias. Labeling, 
hybridization, and scanning were performed by 338
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the Duke University Microarray Core facility as 
described (Clark et al. 2007) and can also be found 
at http://mgm.duke.edu/genome/dna_micro/core/
spotted.htm. A total of 10 chips are included in 
this analysis, with dye-reversed replicates 
performed for each of 5 biological samples: one 
sample each from time 0 and following 24h of 
BCR crosslinking in each the B6 nonautoimmune 
background and the MRL autoimmune background, 
and an additional sample at 24h in the MRL 
background.
Data were imported into GeneSpringGX 7.3 
analysis software, and dye swap and Lowess 
normalizations performed as appropriate. Data 
were initially ﬁ  ltered such that raw and control 
intensity values must be 100 for at least 7 of 
the 10 chips included, ensuring acceptable 
expression levels in at least 3 of the 4 time/strain 
categories. A volcano plot ﬁ  lter was then per-
formed to identify genes whose expression ratio 
(anergic:naïve) differed by greater than 2-fold 
between B6 and MRL strains with a corrected 
p-value of 0.05.
Quantitative PCR
Concentration of cDNA was estimated by spectro-
photometry prior to qPCR and samples all brought 
to similar concentrations prior to analysis. Taqman 
primer/probe mixtures were ordered from Applied 
Biosystems (Foster City, CA, U.S.A.) for Ptpn22 
(assay id Mm00501246_m1), Ap1gbp1 (assay id 
Mm00812653_m1), Birc1f/Naip (assay id 
Mm00783869_s1),  and GAPDH (Mm99999915_g1). 
The primer/probe mixture was combined with 
cDNA and TaqMan Universal PCR Master Mix 
(Applied Biosystems) per the manufacturer’s pro-
tocol. The BioRad iCycler was used for the cycling 
program, with a 10 minute initial hold at 95C fol-
lowed by 40 cycles of 15 seconds at 95C followed 
by 1 minute at 60C. Analysis was performed using 
iQ5 software (Biorad, Hercules, CA, U.S.A.). For 
each primer/probe set, a standard dilution curve 
was performed using puriﬁ  ed clone DNA when 
available (Ap1gbp1) and non-Tg mouse B cell 
cDNA otherwise, with experimental cDNA starting 
gene quantities calculated by interpolation into this 
standard curve followed by normalization to 
GAPDH. Fold change in expression in anergic cells 
was calculated relative to similarly treated and 
concurrently isolated naïve B cells (from non-
transgenic littermates).
Gene Identiﬁ  cation and Network 
Analysis
For each gene identiﬁ  ed as differentially expressed 
by the above criteria, the probe sequence was 
submitted to BLAST (http://www.ncbi.nlm.nih.
gov/BLAST/) to aquire the most up-to-date 
homologies and annotations. The Unigene ID and 
GenBank accession numbers of the best match for 
each gene, generally with 100% identity, were 
collected. These identiﬁ  ers were used to submit 
the data list to both DAVID, or Database for Anno-
tation, Visualization and Integrated Discovery 
(Dennis et al. 2003), to acquire complete onto-
logical (GO) information, and to Ingenuity Path-
way Analysis software (Ingenuity Systems, 
Redwood City, CA, U.S.A.) to assimilate network 
involvement of these genes.
Results
Expression differences in B6 versus 
MRL anergic B cells
Using oligonucleotide microarray assaying 
31,000 oligoprobes, we initially compared genes 
expressed in murine anergic and naïve B cells, 
derived from either autoimmune MRL or healthy 
B6 mice, using Genespring software to generate 
an anergic:naïve expression ratio, where 1.0 
indicates relative increased expression in naïve B 
cells, and 1.0 indicates relative greater expres-
sion in anergic cells (not shown). We next gener-
ated a volcano plot to analyze expression ratios for 
each gene in B6 as compared to the MRL strain, 
using a 2-fold difference and p  0.05 p-value 
cutoff (Fig. 1). This approach identiﬁ  ed 43 probes 
with 2-fold or greater differential expression in B6 
anergic as compared to MRL anergic B cells, stan-
dardized to naïve B cell expression. These probes 
corresponded to 37 characterized genes, listed in 
Table 1. Two genes, CD74 and IgK-V1, were 
identiﬁ  ed by two different probes, whereas four 
additional probe sequences (Table 1, footnote) had 
no 100% homologous described murine sequences 
in GenBank as of February, 2008. Proteins encoded 
by the genes and additional common names for 
selected genes, where available, are included in 
Table 1. Within our cut-off criteria, gene expression 
differences between strains ranged from 2- to 
3-fold. Differential expression was independently 
veriﬁ  ed for three of these genes using real-time 339
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qPCR (Fig. 2). For Ptpn22, the expression 
difference determined by qPCR exceeded 4-fold 
between strains.
To explore the biological signiﬁ  cance of gene 
expression patterns, we analyzed the Gene Ontol-
ogy (GO) classiﬁ  cation using the DAVID Bioin-
formatics Resource, courtesy of the National 
Institute of Allergy and Infectious Diseases. 
Approximately half of the identiﬁ  ed genes cluster 
into six prominently represented ontology groups, 
with multiple genes falling into more than one 
category (Table 1): differentiation, cell cycle, pro-
liferation, development, apoptosis and cell death. 
Other functional groups represented more than 
once in the dataset include signal transduction, 
transcriptional regulation, cytoskeletal organiza-
tion, nucleotide binding, alternative splicing, 
phosphorylation/dephosphorylation, hydrolase, 
and immune response. Expression in B cells has 
been described for a subset of the identiﬁ  ed genes, 
although for many genes the function in B cells is 
poorly explored. The role of some of these genes 
in B cell biology will be discussed below.
Analysis of gene regulatory networks
To further understand the molecular processes engaged 
in anergic cells and disrupted in autoimmunity, Inge-
nuity Pathway Analysis software was used to identify 
regulatory networks enriched amongst the genes 
showing differential expression. This software utilizes 
expert (manually) modeled information derived from 
the full text of articles published in top peer-reviewed 
journals to track molecular interactions. Of the 
37 initially identiﬁ  ed and previously characterized 
genes, 32 were available within the software database 
for network analysis. Two major networks were iden-
tiﬁ  ed (Fig. 3), that incorporated 14 and 12, respectively, 
non-overlapping qualifying genes. Network 1 centers 
on beta-estradiol, and Network 2 encompasses 
cell growth, proliferation and cell cycle signaling 
pathways.
These networks integrate members of multiple 
functional subpathways, as suggested by GO 
analysis and including apoptosis, mitogen-acti-
vated protein kinase (MAPK) and nuclear factor 
kappaB (NFkB) signaling, and actin cytoskeletal 
interactions. Major hubs of Network 1 show that 
genes with differential expression interact with or 
are regulated via beta-estradiol, homeobox A9 
(HoxA9) and Arnt2. Three additional qualifying 
genes, Eif4G2, Mier1 and Glipr1, are incorporated 
within the beta-estradiol regulated network when 
Network 1 is extended to include interactions with 
the TP53 gene that encodes transcriptional regula-
tor protein p53. Hubs of Network 2 indicate cross-
talk and regulation through Rb1, Cdc2, P38/MAPK, 
NFkB, Pdgf-BB, the actin family, histone H3, and 
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Figure 1. A volcano plot was used to visualize and identify genes, shown in red, whose expression ratio between anergic and naïve B cells 
differed between MRL and B6 strains. Cutoff criteria for differential expression in this analysis is deﬁ  ned as a minimum fold change of 2.0, 
plotted on the X axis, with a multiple testing corrected p-value (plotted on the Y axis) of less than 0.05.340
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Table 1A. Gene ontology of differentially expressed transcripts identifed by microarray.
Gene  Ratio anergic: naïve
symbol Description  B6  MRL  Ontologic  categories 
Genes increased 2-fold or more in B6 relative to MRL anergic B cells. 
Loh11cr2a  Loss of hyeterozygosity 11  2.85  0.95  Cyc 
Prei4  Preimplantation protein 4  1.48  0.61  Hydrolase, carbohydrate 
metabolism 
Glipr1 GLI  pathogenesis-related 
1 
2.36 1.01  Apop,  Sig  Trans 
Ptpn22 Protein  tyrosine 
phosphatase 
3.61 1.56 Apop, Growth, Diff, Sig 
Trans, Dev, Phos
non-receptor type 22 
Tmbim1 Transmembrane  BAX 
inhibitor 
2.32 1.05  Alternative  splicing 
motif containing 1 
Smc2  Structural maintenance of 
chrom.2 
1.06  0.48  Cyc, Nuc, chromosome 
organization 
Nup153  Nucleoporin 153  1.14  0.52  Nuc, protein binding, 
transporter 
Rb1  Retinoblastoma 1  1.28  0.59  Cyc, Phos, Trans reg, 
Diff, Prolif, Dev, Apop, 
Death 
Eif4g2 Eukaryotic  translation 
initiation 
1.10  0.50  Nuc, Cyc., death, 
transcription initiation 
factor 4 gamma 2 
EG622976 1.45 0.67 none
Ugdh UDP-glucose 
dehydrogenase 
1.32  0.61  Dev, electron transport 
Kpna2 karyopherin  (importin) 
alpha 2 
1.25 0.58  DNA  recombination 
regulation 
Ctla4 Cytotoxic  T-lymph-assoc. 
protein 4 
1.96 0.91  Immune  response 
Mbnl1  Muscleblind-like 1  1.85  0.87  Diff, RNA binding 
Pkib  Protein kinase inhibitor 
beta 
1.24  0.59  Diff, kinase inhibitor 
Birc1f Baculoviral  IAP 
repeat-containing 1f
2.03 0.96 Apop, death
or Naip6 
Cept1 choline/ethanolamine 
phosphor-transferase 1
1.52 0.73 Lipid metabolism
Cdc2a Cell division cycle 2 
homolog A
1.51 0.73 Apop, Nuc, Cyc, Phos, 
mitosis, DNA damage 
response
Plekha1 Pleckstrin  homology 
domain 
1.22 0.61 lipid binding, alternative 
splicing
containing family A   
Med23  Mediator subunit SUR2  1.20  0.59  Trans reg, metastasis 
suppressor 341
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Genes decreased 2-fold or more in B6 relative to MRL anergic B cells. 
Akap13  A kinase (PRKA) anchor 
protein 13 
0.91 1.83 Sig Trans
or BRX 
Actc1  Actin, alpha, cardiac  0.93  1.90  Dev, Nuc, Cytoskeletal 
organization 
Tcof1 Treacher  Collins 
Franceschetti syndrome 1 
homolog
0.69 1.42 Prolif, Phos, transport, 
transcription
Aldoart2  Aldolase 1, A isoform, 
retrogene 2 
0.91 1.89  none 
GALNAC4S-
6ST 
B cell Rag-Associated 
protein 
0.81 1.70  Catalytic  activity 
Ankrd11  Ankyrin repeat domain 11  1.05  2.20  Nuc 
Mef2c  Myocyte enhancer factor 
2C 
0.91  1.92  Apop, Diff, Phos, Trans 
reg, Dev 
Grap2 GRB2-related  adaptor 
protein 2 
0.65 1.38  Sig  Trans,  cell 
communication 
Ddx46  DEAD box polypeptide 46  0.77  1.68  Nuc, RNA binding/
splicing, hydrolase 
CD74  CD74 antigen  0.84  1.85  Prolif, Apop, Sig Trans, 
Immune response 
Phf17 PHD  ﬁ  nger protein 17, 
Jade1 
0.81  1.79  Apop, Dev, cell growth 
Ap1gbp1  Ap1 gamma binding 
protein 1 
0.67  1.50  ion binding, protein 
localization 
Esco1 Establishment  of 
cohesion 1 
1.16  2.63  Cyc, alternative splicing, 
metal/ion binding 
Igk-V1  Ig kappa V1  2.06  4.77  Immune Response 
Actg2  Actin, gamma 2, smooth 
muscle 
0.86 2.29  Nuc,  Cytoskeletal 
organization, Dev. 
Mier1  Mesoderm induct. early 
response-1 
0.80  2.14  Nuc, Sig Trans, Phos., 
Trans reg 
Actb  Similar to cytoskeletal beta 
actin 
0.94 2.56  Nuc,  Cytoskeletal 
organization 
1. Genes represented by two probes are CD74 and Igk-V1. Expression ratios for one probe for each gene is shown in the table. Ratios for 
the second probe were 0.72 (B6) and 1.77 (MRL) for CD74, and 1.38 (B6) and 3.18 (MRL) for Igk-V1. GALNAC4S-6ST corresponds to 
Unigene 4631426J05Rik. Four genes or probes were omitted from the table due to absence of a known 100% homologous murine coding 
sequence. Operon identiﬁ  ers for the omitted probes are M300017393, M300013500, M300019467, and M300013958.
2. Common GO categories: Development = Dev, Differentiation = Diff, Apoptosis = Apop, Proliferation = Prolif, Cell Cycle = Cyc, Cell Death = 
Death, Phosphorylation/Dephosphorylation = Phos, Transcriptional regulation = Trans reg, Signal Transduction = Sig Trans, Nucleotide 
binding = Nuc.
3. The ratios shown in the tables are the mean normalized values (across 4–6 chips) for the gene expression in anergic B cells relative to 
naive B cells for each strain. This is based on two-color competitive hybridization on each chip, pairing anergic B cell aRNA and naive B cell 
aRNA from the same mouse strain. The ratio of expression for each gene for each strain was generated, and these ratios were then compared 
between strains.
Table 1B. 
Gene  Ratio anergic: naïve
symbol Description  B6  MRL  Ontologic  categories 342
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Figure 2. Quantitative PCR veriﬁ  cation of three genes identiﬁ  ed by microarray as differentially regulated in anergic B cells in the B6 versus 
MRL backgrounds. Unstimulated B cells were isolated from transgenic and nontransgenic mice in both backgrounds and quantiﬁ  ed by RT-
PCR using pre-designed TaqMan probe/primer sets. Relative copy number was calculated after normalization to expression levels of GAPDH 
in each sample. Shown is the ratio of anergic:naive transcript levels in each background. Genes shown are Ptpn22, protein tyrosine phos-
phatase non-receptor type 22; Birc1f baculoviral IAP repeat-containing 1f, also known as Naip6, or neuronal apoptosis inhibitory protein 6; 
and Ap1gbp1, AP1 gamma binding protein 1.
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insulin. Although not shown in Figure 3, the two 
major networks are interconnected by several 
interactions, including crosstalk between TP53 and 
Rb1 gene products, and Pkib regulation of various 
MAPK, extracellular signal-regulated kinase 
(ERK) and protein kinase A (PKA) pathways. 
Some signaling components are omitted from the 
displayed networks for the sake of clarity.
Conclusion
We used oligoarray probes and an autoantibody 
transgenic model to identify 43 probes representing 
37 characterized genes that are differentially 
expressed by 2-fold or more in B cells anergized 
within the context of the nonautommune B6 as 
compared to lupus-prone MRL genetic back-
grounds. To our knowledge this is the ﬁ  rst global 
gene expression analysis of anergic B cells derived 
from strains differentially susceptible to systemic 
lupus. The data provide evidence that autoimmune 
susceptibility alters B cell anergy at the level of 
gene expression. Identiﬁ  ed genes include Ptpn22, 
previously identiﬁ  ed as important in human auto-
immunity and a potential therapeutic target, and 
CD74, a key modulator of B cell maturation and 
survival. Our ﬁ  ndings are the ﬁ  rst to link these 
molecules to B cell anergy. Gene Ontology catego-
ries development, differentiation, cell cycle, 
proliferation, apoptosis, and cell death were 
prominently represented. These categories also 
include cell functions known to be affected by 
previously described abnormalities associated with 
genetic or environmental susceptibility to systemic 
autoimmunity. Network analysis using Ingenuity 
Pathway Analysis software revealed that at least 
26 of the identiﬁ  ed genes are interconnected by 
signaling and regulatory pathways well described 
in immune and inﬂ  ammatory responses, with nodes 
at TP53, Rb1, NFkB, P38/MAPK, Pdgf-BB and 
Cdc2. Network analysis also unmasked beta-
estradiol at the center of one module interacting 
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Figure 3. Network analysis of genes differentially expressed in B6 versus MRL anergic B cells. Ingenuity software generated two major 
networks (labeled 1 and 2) interconnecting multiple array-identiﬁ  ed genes (shown in solid blue for expression lower in B6 than MRL and in 
red for higher expression in B6). The numbers displayed below array-identiﬁ  ed genes indicate relative fold-change in B6 anergic cells. The 
networks summarize interactions between functional pathways and the genes that are altered in expression.344
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with 11 qualifying genes. Collectively, these results 
suggest an important role for these genes and sig-
naling networks in the biology of anergy and 
autoimmune genetic susceptibility.
Several differentially expressed genes deserve 
emphasis. Our array ﬁ  ndings are the ﬁ  rst to link 
Ptpn22 to anergy. Ptpn22, tyrosine phosphatase non-
receptor type 22, is a hematopoietic cell-speciﬁ  c 
intracellular phosphatase and known negative 
regulator of antigen receptor signaling in lympho-
cytes (Cloutier and Veillette, 1999; Hasegawa et al. 
1999). Our arrays showed that an oligonucleotide 
corresponding to Ptpn22, and the mouse orthologue 
Ptpn8, is upregulated in anergic as compared to 
naïve B cells in both B6 and MRL mice, but with 
a two-fold higher level in B6 cells. Ptpn22 encodes 
a proline-, glutamic acid-, serine- and threonine-
rich (PEST)-enriched tyrosine phosphatase, Lyp 
(human) or PEP (mouse) (Cohen et al. 1999; 
Wicker et al. 2005). In man, the C1858T (R620W) 
allelic variant of Ptpn22 has been linked to mul-
tiple human autoimmune disorders that have a 
prominent humoral component, including SLE, 
rheumatoid arthritis, type 1 diabetes, and autoim-
mune thyroiditis (Begovich et al. 2004; Bottini 
et al. 2004; Criswell et al. 2005; Gregersen et al. 
2006; Kyogoku et al. 2004; Lauwerys and 
Wakeland 2005; Smyth et al. 2004). The role of 
Ptpn22/Ptpn8 as a susceptibility gene in mouse 
autoimmune diseases is less well characterized, 
although gene variants have been linked to type 1 
diabetes in NOD mice (Wicker et al. 2005). Much 
of current knowledge of Ptpn22 function derives 
from studies of T cells and PEP, which implicate 
PEP in dephosphorylation of Src family kinases. 
The human R620W allele was recently determined 
to encode enhanced inhibitory function of the 
phosphatase, and individuals with the allele have 
dampened B and T cell receptor signaling (Rieck 
et al. 2007; Vang et al. 2005). These biological 
consequences were unanticipated, and fuel specu-
lation that autoimmunity is caused by an aberrant 
Lyp-induced raised signaling threshold in lympho-
cytes of affected individuals, such that self-antigen 
contact fails to trigger tolerance induction. Our 
array results suggest that in healthy B6 mice an 
upregulated Ptpn22/Ptpn8 may be one mechanism 
for maintaining nonresponsiveness in anergic cells, 
perhaps via the raised signaling threshold, and that 
this mechanism is abrogated in autoimmune MRL 
mice. In cells from the MRL strain, the relative 
expression of Ptpn22 in the anergic:naïve subsets 
varied depending on the method of detection (array 
and qPCR), suggesting an inﬂ  uence of gene poly-
morphisms, splice variants, or other factors; protein 
expression studies should help resolve this point. 
The role of Ptpn22 in tolerance needs further 
exploration in anticipation of clinical application 
of recently developed Lyp inhibitors (Yu et al. 
2007). It is notable that Pep-deﬁ  cient mice fail to 
spontaneously develop overt autoimmunity, 
although they do develop large germinal centers, 
increased Ig concentrations, enhanced TCR-medi-
ated signaling, and increased numbers of splenic 
CD4+ and CD8+ effector/memory T cells 
(Hasegawa et al. 2004).
B6 and MRL anergic B cells also vary by 2-fold 
or more in their expression of CD74, a nonpoly-
morphic Type II transmembrane protein, MHC 
Class II chaperone, and dormant transcription fac-
tor known to inﬂ  uence B cell biology. The relative 
expression of CD74 in anergic versus naïve B cells 
is inverse in the two mouse strains: CD74 is rela-
tively downregulated in anergic cells from B6 
mice, but upregulated in anergic cells from autoim-
mune-prone MRL mice. Although CD74 has not 
previously been linked to anergy, tolerance or 
autoimmunity, it has several biologic functions 
consistent with such a role. CD74 is crucial for B 
cell maturation, as shown in mice deﬁ  cient in CD74 
(Shachar et al. 1995; Viville et al. 1993). Recent 
studies reveal additional roles for CD74 in promot-
ing B cell differentiation, proliferation and survival 
(Benlagha et al. 2004; Gore et al. 2008; Lantner 
et al. 2007; Shachar and Flavell, 1996; Starlets 
et al. 2006), and suggest a therapeutic role for 
antagonistic anti-CD74 antibodies in diseases 
marked by B cell overactivity (Stein et al. 2007).
The natural ligand for CD74 in B cells is 
unclear, although the CD74 extracellular domain 
is known to have high-afﬁ  nity for the proinﬂ  am-
matory macrophage migration-inhibitory factor, 
MIF. CD74 is implicated in several MIF-mediated 
cell responses in mouse macrophages and the 
human Raji B cell line (Leng et al. 2003), includ-
ing ERK, Syk and PI3K/Akt phosphorylation. 
Subsequent intramembrane proteolytic cleavage 
of CD74 triggers its nuclear translocation to induce 
transcription via NF-kB p65/RelA homodimer and 
its coactivator, TAF(II)105 (Becker-Herman et al. 
2005; Matza et al. 2002a; Matza et al. 2002b; 
Matza et al. 2001; Starlets et al. 2006). MIF-
induced CD74 signaling in B cells requires forma-
tion of a complex with CD44 (Gore et al. 2008), a 345
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molecule shown to be increased in both B6 and 
MRL unstimulated anergic B cells (microarray data 
not shown; cell surface expression in B6 mice is 
described in Brady et al. 2004).
Two additional genes identiﬁ  ed as differentially 
expressed in anergic B6 as compared to MRL B 
cells have functions either known or anticipated to 
modulate autoimmunity. Cytotoxic T lymphocyte 
antigen-4, also known as Ctla-4 or CD152, a trans-
membrane protein primarilyknown as a major 
inhibitor of T cell responses (Teft et al. 2006), is 
upregulated in B6 relative to MRL anergic B cells 
in our array studies. This suggests a negative 
regulatory role for B cell CTLA-4, consistent with 
recent results in bone marrow chimeric mice in 
which CTLA-4 deﬁ  ciency was restricted to B cells 
(Quandt et al. 2007). Birc1f, or baculoviral IAP 
repeat-containing 1f, also known as neuronal apop-
tosis inhibitory protein or Naip, is inversely regu-
lated in B6 and MRL anergic B cells. Birc1f is a 
Nod-like and pathogen pattern recognition recep-
tor and one of the four main deﬁ  ning groups of the 
newly described CATERPILLER family of 
proteins implicated in immunity and inﬂ  amma-
tion (Ting et al. 2006). Although its function in 
B cells is unknown, it is notable that Birc1f is 
downregulated during endotoxin-induced matura-
tion of human dendritic cells from an immature 
tolerogenic to an immunogenic mature phenotype 
(Matsunaga et al. 2002). By analogy, Birc1f down-
regulation in MRL anergic B cells may promote 
enhanced cell survival and antigen presenting func-
tions that in turn promote autoimmunity. For mul-
tiple additional genes in our panel, including 
Mbnl1, Phf17, Prei4, Loh11cr2a, Glipr1, Tmbim1, 
Smc2, Tcof1, Ugdh, transcriptional activator 
Med23/Sur2, Actg2, Esco1, Ddx46, Ap1gbp1, 
Ankrd11, Actc1, Aldoart2, and Cept1, little is cur-
rently known about their biology in B cells.
In addition to identifying individual genes that 
may act independently to modify anergy and auto-
immunity, our array studies identiﬁ  ed molecular 
interactions and signaling networks that may have 
an additive or synergistic impact on tolerance and 
autommunity. Perhaps most notable, network 
analysis revealed an unexpected and central role 
for beta-estradiol inﬂ  uences in the maintenance of 
B cell anergy. Estradiol interacts with at least 11 
genes, or their protein products, identiﬁ  ed by our 
array analysis. Estrogens have long been suspected 
of promoting systemic autoimmunity due to the 
striking female predominance, including a 
female-to-male ratio of 10:1 in human SLE and 
earlier disease onset in females in some murine 
lupus models, such as (NZBxNZW)F1 mice 
(Andrews et al. 1978). Moreover, administration 
of exogenous estrogen has been shown to induce 
autoantibodies in non-autoimmune mice and accel-
erate disease in lupus-prone mice of both sexes, 
whereas ovariectomy or administration of testos-
terone to female lupus mice ameliorates disease 
(Apelgren et al. 1996; Melez et al. 1980; Roubin-
ian et al. 1978; Steinberg et al. 1980; Verthelyi and 
Ahmed 1994; Verthelyi and Ahmed 1998).
The underlying cellular and molecular mecha-
nisms for hormone linked effects are still not well 
understood. B cells express both estrogen receptor 
(ER)-alpha and ER–beta, although relative levels 
vary during cell development (Grimaldi et al. 
2002). Exposure of healthy mice to elevated levels 
of estradiol alters expression of molecules known 
to regulate B cell receptor signaling (Grimaldi et al. 
2002) and suppresses B cell lymphopoiesis 
(Kincade et al. 2000). Non-autoimmune mice 
rendered genetically deﬁ  cient in estrogen or its 
receptors develop expanded B lymphoid and 
myeloid cell pools (Shim et al. 2003), plasmacy-
tosis (Shim et al. 2004a), and autoimmunity (Shim 
et al. 2004a; Shim et al. 2004b), including lupus-
like immune complex glomerulonephritis (Shim 
et al. 2004a), whereas induction of ER-alpha deﬁ  -
ciency in (NZBxNZW)F1 lupus mice leads to 
amelioration of autoimmune disease (Bynote et al. 
2008). These ﬁ  ndings are difﬁ  cult to reconcile, and 
suggest complex hormonal effects on B cell biol-
ogy and immunity.
Novel insight into the role of estrogen in 
immune tolerance was provided in an elegant series 
of studies from Diamond and colleagues showing 
that estrogen blocks deletion of anti-DNA B cells 
at the transitional cell stage (Bynoe et al. 2000; 
Grimaldi et al. 2002; Grimaldi et al. 2006; Grimaldi 
et al. 2001; Venkatesh et al. 2006). Prolonged 
administration of 17beta-estradiol to Balb/c mice 
bearing the R4A-gamma2b H chain Ig transgene 
induced CD4 T cell-independent autoantibody 
production, bcl-2 expression, and expansion 
of unmutated high afﬁ  nity anti-DNA B cells that 
are normally tolerized by anergy and deletion 
(Bynoe et al. 2000; Grimaldi et al. 2001). Estrogen-
induced elevation in levels of B cell activating 
factor, or BAFF (also known as B-lymphocyte 
stimulator or BLyS) has been implicated (Grimaldi 
et al. 2006).346
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Our array results indicate that estrogen directly 
or indirectly interacts with molecules differentially 
engaged in maintenance of B cell anergy in B6 as 
compared to lupus-prone MRL mice. Estrogen-
linked genes relatively upregulated in B6 as com-
pared to MRL anergic cells include Ptpn22 and 
Ctla-4 (see above), Mbnl1, Med23, Nup153, 
Kpna2, and Pkib. Little is known about B cell 
functions of many of these genes. Nup153 is a 
nucleoporin and an autoantibody target in lupus 
(Ball and Ullman, 2005; Enarson et al. 2004). The 
B cell functions of Kpna2, or karyopherin alpha 2, 
also known as importin alpha 1, a protein engaged 
in nuclear transport and modulation of cell prolif-
eration (Kussel and Frasch, 1995), are yet to be 
elucidated. Estradiol interacts with the protein 
kinase inhibitor, Pkib, both directly and via Arnt2, 
the arylhydrocarbon receptor nuclear translocator 
2 that encodes a basic helix-loop-helix/PAS (Per-
Arnt-Sim) transcription factor. Our array results 
suggest that the relative decrease in Pkib’s negative 
regulatory functions in MRL anergic B cells may 
contribute to autoimmunity.
Estradiol may regulate some genes in our panel 
indirectly through its effects on transcription, 
phosphorylation, and localization of the tumor 
suppressor protein p53 (Bond and Levine, 2007), 
encoded by gene TP53 (Fig. 3). Protein p53 is a 
nuclear phosphoprotein and DNA-binding tran-
scription factor that regulates the cell cycle and 
apoptosis. Dysregulation of p53 pathways can 
induce lupus-like autoimmunity (Salvador et al. 
2002), and p53 is itself a target of lupus autoanti-
bodies (Herkel et al. 2001). TP53 interacts with 
three additional array-identiﬁ  ed genes whose func-
tions in B cells are not yet characterized: Glipr1 
and Eif4G2, genes relatively upregulated in B6 
versus MRL anergic B cells, and Mier1, which is 
relatively downregulated in B6 cells. Glioma 
pathogenesis-related protein (Glipr1) is a novel 
p53 target gene with proapoptotic activities in 
tumor cells (Li et al. 2008), whereas the translation 
initiation factor Eif4G2 has effects on the cell cycle 
(Lee and McCormick, 2006). Mesoderm induction 
early response gene 1, or Mier1, functions as a 
transcriptional repressor of a number of genes, 
including targets of transcription factor Sp1, 
through recruitment of histone deacetylase 1 
(Hdac1), a major regulator of chromatin structure 
and gene expression (Ding et al. 2003). Although 
Mier1 expression and Hdac1 functions in B cells 
are not well characterized, Hdac1 is ubiquitously 
expressed in lymphoid tissues, and Hdac inhibitors 
have been used to induce cell cycle arrest and 
downregulate inﬂ  ammatory cytokines and nephri-
tis in MRL/lpr lupus mice (Mishra et al. 2003).
In contrast to the genes described above, several 
estrogen-interacting genes are relatively upregu-
lated in lupus-prone MRL, as compared to B6, 
anergic B cells. These include Akap13, GalNAc4S-
6ST and Ankrd11. Akap13, or PKA anchoring 
protein 13, also known as breast cancer nuclear 
receptor auxiliary factor or BRX, is a scaffold 
protein with Rho guanine nucleotide exchange 
factor activity that integrates extracellular signaling 
through Rho familyGTPase, PKA, p38/MAPK and 
NFkB. These pathways enhance nuclear hormone 
receptor signaling and transcriptional activity of 
ER-alpha and beta (Driggers et al. 2001; Kino et al. 
2006; Rubino et al. 1998; Shibolet et al. 2007). 
GalNAc4S-6ST, also known as B cell Rag-
associated protein or BRAG, is reported to enhance 
BCR signaling (Verkoczy et al. 2000). Relative 
upregulation of Akap13 and GalNAc4S-6ST in 
MRL B cells may promote cell activation or bypass 
of anergy. Little is currently known about the bio-
logical functions of ankyrin repeat domain 11, or 
Ankrd11.
The mechanisms through which estrogen inter-
acts with genes and proteins in B cells remains 
poorly understood. A role in processes maintaining 
anergy is consistent with estrogen’s actions on 
non-lymphoid cells: estrogen regulates growth, 
proliferation, survival, and apoptosis through the 
classical ER-alpha and ER-beta and their func-
tional splice variants, as well as through putative 
nonclassical membrane-localized receptors, of 
which G-protein-coupled receptor (GPR)30 is best 
characterized. ER-alpha and ER-beta regulate 
unique gene expression patterns, mediate isoform-
speciﬁ  c and often opposing effects on cell func-
tions, and cross-regulate each other’s expression 
and actions, through two distinct signaling path-
ways. In the delayed nuclear (formerly, genomic) 
pathway, ER acts as a ligand-dependent transcrip-
tion factor that binds target gene promoters, 
whereas a rapid cell membrane-initated (nonge-
nomic) pathway activates MAPK and PI3K/Akt 
signaling (Moriarty et al. 2006). Better character-
ization of the pathways regulated by estradiol 
during selection of autoreactive B cells should 
facilitate understanding of the sexual dimorphism 
of lupus susceptibility and lead to new therapeutic 
targets in SLE.347
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In addition to the estradiol and TP53 network, 
our array analysis linked an additional 13 genes, 
including CD74 discussed in detail above, Cdc2, 
Mef2c, Grap2 and Plekha, to a second intercon-
necting network with major nodes at molecules 
known to be key in B cell receptor signaling 
(NFkB, MAPK) and proliferation (retinoblastoma 
gene, Rb1). For several of these genes, their 
relative expression level in B6 as compared to 
MRL anergic cells runs counter to what might be 
anticipated based on current limited understand-
ing of their biology. Rb1 protein was previously 
linked to B cell tolerance in a murine lymphoma 
model (Joseph et al. 1995). Rb1 hypophosphory-
lation and inhibition are associated with cell cycle 
and growth arrest (Bilancio et al. 2006; Joseph 
et al. 1995). It is notable that B cell survival fac-
tor BAFF/BlyS, a therapeutic target in SLE, 
promotes B cell Rb1 synthesis and phosphoryla-
tion (Huang et al. 2004). The signiﬁ  cance of 
relative Rb1 upregulation in our B6 anergic cells 
is unclear. RB1 crossregulates Cdc2 and Mef2c, 
genes relatively up and down regulated, respec-
tively, in B6 as compared to MRL anergic B cells. 
Impaired function of cell cycle regulator and 
cyclin-dependent kinase Cdc2 has been linked to 
T cell tolerance (Li et al. 2006). Mef2c, or myo-
cyte enhancer factor 2, belongs to a small family 
of calcineurin-regulated calcium-dependent tran-
scriptional regulators of lymphocyte signaling, 
cytokine production and apoptosis (Esau et al. 
2001; Youn et al. 1999). Mef2c was recently 
determined to be critical to B cell receptor-
induced cell proliferation and survival (Wilker 
et al. 2008). GRB2-related adaptor protein 2, or 
Grap2, and pleckstrin homology domain contain-
ing family A (phosphoinositide binding speciﬁ  c) 
member 1, or Plekha/TAPP1, genes down-and 
upregulated, respectively in B6 anergic cells, were 
recently determined to modulate B cell receptor 
signaling (Allam and Marshall, 2005; Garrett-
Sinha et al. 2005). Neither Mef2c, Grap2, or 
Plekha was previously linked to tolerance or 
autoimmunity.
Although much remains to be done to elucidate 
the role of many of these genes in B cell anergy, 
this work represents a ﬁ  rst attempt to identify genes 
and proteins that underlie failure of B cell tolerance 
in autoimmunity. Ongoing studies are using this 
information in an attempt both to identify cellular 
markers of anergy, with the hopes of translating 
these ﬁ  ndings to description and isolation of human 
anergic cells, and to identify potential clinical 
targets for therapeutic intervention to prevent or 
ameliorate disease.
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